MCM
CSTL icon

MAI Capital Management’s Castle Biosciences CSTL Stock Holding History

MAI Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19
Closed -$467 – 2644
2026
Q1 		$467 Buy
+19
New +$622 ﹤0.01% 4432

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MAI Capital Management's CSTL Position: Q2 2026 in Review

MAI Capital Management sold out of Castle Biosciences (CSTL) in Q2 2026, closing a stake of 19 shares — an estimated $467 sold.

MAI Capital Management first reported a position in CSTL in Q1 2026 and held it in 1 quarter. The position peaked at $467 in Q1 2026. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • MAI Capital Management reported no remaining Castle Biosciences position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 19 Castle Biosciences shares in Q2 2026, an estimated $467.
  • MAI Capital Management first reported a position in Castle Biosciences in Q1 2026 and held it in 1 quarter.
  • MAI Capital Management's Castle Biosciences position peaked at $467 in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.